American Journal of Medical and Biological Research
ISSN (Print): 2328-4080 ISSN (Online): 2328-4099 Website: Editor-in-chief: Apply for this position
Open Access
Journal Browser
American Journal of Medical and Biological Research. 2019, 7(1), 1-5
DOI: 10.12691/ajmbr-7-1-1
Open AccessArticle

Nephrotoxicity Induced by Cytosar in Rabbits Kidneys (A Histological Study)

Saif Al-Jammas1,

1Basic Sciences, College of Dentistry\Mosul University, Mosul, Iraq

Pub. Date: June 02, 2019

Cite this paper:
Saif Al-Jammas. Nephrotoxicity Induced by Cytosar in Rabbits Kidneys (A Histological Study). American Journal of Medical and Biological Research. 2019; 7(1):1-5. doi: 10.12691/ajmbr-7-1-1


The current study was carried out to assess the nephrotoxicity induced by Cytosar in kidneys of rabbits from the histological aspect. The treated group with a dose of (50 mg/kg/daily) of Cytosar for 5 days, showed clear histological changes represented by glomerular atrophy and widening of Bowman’s spaces, infiltration of lymphocytes and macrophages within cortex, renal tubular necrosis, cortical hemorrhage and fibrosis as well as formation of tubular hyaline cast was also observed. The present study showed that Cytosar is a nephrotoxic drug when used repeatedly at this dosage which could lead to irreversible renal damage and finally renal failure.

Cytosar nephrotoxicity rabbits kidneys

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


Figure of 7


[1]  Momparler, R.L., "Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia," Exp Hematol Oncol, 6 (2). 20. 2013.
[2]  Rechkoblit, O., Choudhury, J.R., Buku, A., Prakash, L., Prakash, S. and Aggarwal, A.K., "Structural basis for polymerase η-promoted resistance to the anticancer nucleoside analog Cytarabine," Sci Rep, 8 (1). 12702. Aug. 2018.
[3]  Konda, N., Prashanth, P., Arvind, G. and Shah S., "Pharmaceutical development and compatibility studies on Cytarabine injection," Asian J. Pharm. Clin. Res, 3 (6). 142-145. 2013.
[4]  Norbert, L., "Nephrotoxicity of recent anti-cancer agents," Clin Kidney J, 7 (1). 11-22. 2014.
[5]  Löwenberg, B., Pabst, T., Vellenga, E., et al., "Cytarabine dose for acute myeloid leukemia," N Engl J Med, 364 (11). 1027-1036. 2011.
[6]  Perazella, M.A., "Onco-Nephrology: Renal Toxicities of Chemotherapeutic Agents," Clin J Am Soc Nephrol, 7 (10). 1713-1721. 2012.
[7]  Morrissey, K.M., Stocker, S.L., Wittwer, M.B., Xu, L. and Giacomini, K.M., “Renal transporters in drug development,” Annu Rev Pharmacol Toxicol, 53. 503-529. 2013.
[8]  Malyszko, J., Kozlowska, K., Kozlowski, L. and Malyszko, J., “Nephrotoxicity of anticancer treatment,” Nephrol Dial Transplant, 32 (6). 924-936. 2017.
[9]  Pazhayattil, G.S. and Shirali, A.C., “Drug-induced impairment of renal function,” Int J Nephrol Renovasc Dis, 7. 457-468. 2014.
[10]  Izzedine, H. and Perazella, M.A., “Anticancer Drug-Induced Acute Kidney Injury,” Kidney Int Rep, 2 (4). 504-514. 2017.
[11]  Rodríguez-Iturbe, B., Vaziri, N.D., Herrera-Acosta, J. and Johnson, R.J., “Oxidative stress, renal infiltration of immune cells, and salt-sensitive hypertension: all for one and one for all,” Am J Physiol Renal Physiol. 286 (4). 606-616. 2004.
[12]  Miller, R.P., Tadagavadi, R.K., Ramesh, G. and Reeves, W.B., “Mechanisms of Cisplatin nephrotoxicity,” Toxins (Basel), 2 (11). 2490-2518. 2010.
[13]  Al-Jammas, S. and Al-Hubaity, A.Y., “The Effects of Vitamin C on the Structure of Wistar Albino Rat's kidney,” Medical Journal of Tikrit, 2 (172). 116-119. 2011.
[14]  Choi. Y.M., Kim, H.K., Shim, W., et al., “Mechanism of Cisplatin-Induced Cytotoxicity Is Correlated to Impaired Metabolism Due to Mitochondrial ROS Generation,” PLoS One, 10 (8). e0135083. 2015.
[15]  Liu, Y., “Cellular and molecular mechanisms of renal fibrosis,” Nat Rev Nephrol, 7 (12). 684-696. 2011.
[16]  Abdelhalim, M. and Jarrar, B.M., “The appearance of renal cells cytoplasmic degeneration and nuclear destruction might be an indication of GNPs toxicity,” Lipids in Health and Disease, 10. 147. 2011.
[17]  Lawenda, B.D., Kelly, K.M., Ladas, E.J., Sagar, S.M., Vickers, A. and Blumber, J.B., “Should Supplemental Antioxidant Administration Be Avoided During Chemotherapy and Radiation Therapy?,” J Natl Cancer Ins, 100. 773-783. 2008.
[18]  Hutchison, C.A., “Batuman V, Behrens J, et al. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma,” Nat Rev Nephrol, 8 (1). 43-51. 2011.